meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immunostimulant
vs interferon alpha
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
Gender, female
Gender, male
PD-L1 < 1%
PD-L1 > 1%
stage IIIa
stage IIIb
stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DMFS
MFS
RFS (extension)
RFS/DFS
AE (any grade)
AE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Adrenal insufficiency TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sarcoidosis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
DMFS
mML - NA - all population
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
versus placebo
pembrolizumab alone vs. placebo
1
certainty unassessable
statistically conclusive
-37%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open